Versant Capital Management’s Mineralys Therapeutics MLYS Stock Holding History

Versant Capital Management’s Portfolio MLYS Stock Details MLYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$13.8K	Hold	513	–	–	﹤0.01%	2110
2026 Q1	$13.9K	Hold	513	–	–	﹤0.01%	1989
2025 Q4	$18.6K	Hold	513	–	–	﹤0.01%	1687
2025 Q3	$19.5K	Hold	513	–	–	﹤0.01%	1593
2025 Q2	$6.94K	Buy	513 +82	+19%	+$1.19K	﹤0.01%	2051
2025 Q1	$6.84K	Buy	431 +378	+713%	+$4.35K	﹤0.01%	1909
2024 Q4	$652	Sell	53 -10	-16%	-$131	﹤0.01%	2250
2024 Q3	$763	Hold	63	–	–	﹤0.01%	1802
2024 Q2	$737	Hold	63	–	–	﹤0.01%	1730
2024 Q1	$813	Hold	63	–	–	﹤0.01%	1588
2023 Q4	$542	Buy	+63	New	+$495	﹤0.01%	1659
2023 Q3	–	Sell	-32	Closed	-$546	–	2009
2023 Q2	$546	Buy	+32	New	+$478	﹤0.01%	1814

Other funds holding MLYS

Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Versant Capital Management's MLYS Position: Q2 2026 in Review

Versant Capital Management held its Mineralys Therapeutics (MLYS) position steady in Q2 2026 at 513 shares worth $13.8K. The position accounts for ﹤0.01% of the portfolio, ranked #2110.

Versant Capital Management first reported a position in MLYS in Q2 2023 and has held it in 12 quarters since. The position peaked at $19.5K in Q3 2025. 224 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

Versant Capital Management held 513 shares of Mineralys Therapeutics worth $13.8K as of Q2 2026.
Versant Capital Management left its Mineralys Therapeutics share count unchanged in Q2 2026.
Mineralys Therapeutics made up ﹤0.01% of Versant Capital Management's portfolio in Q2 2026, its #2110 holding.
Versant Capital Management first reported a position in Mineralys Therapeutics in Q2 2023 and has held it in 12 quarters since.
Versant Capital Management's Mineralys Therapeutics position peaked at $19.5K in Q3 2025.
224 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.